drugset
Drugs / Trimer 4571
last change Jan 2026 re-read 2 minutes ago

Trimer 4571

also known as VRC-HIVRGP096-00-VP · HIV-1 Trimer 4571 Vaccine

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Access to Advanced Health Institute (AAHI) · Department of Health and Human Services · HIV Vaccine Trials Network · Dynavax Technologies Corporation · Fred Hutchinson Cancer Center
+6 more · Inovio Pharmaceuticals · International AIDS Vaccine Initiative · Madhu Chhanda Choudhary · National Institutes of Health (NIH) · The Betty and Dale Bumpers Vaccine Research Center (VRC) · The Wistar Institute

Trials 8 · a red edge is where a trial was stopped

today NCT06332339 · Ph 1 NCT05781542 · Ph 1 NCT05828095 · Ph 1 NCT05470400 · Ph 1 NCT04985760 · Ph 1 NCT04177355 · Ph 1 NCT03878121 · Ph 1 NCT03783130 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06332339 Mar 2024 → Nov 2026 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded
Phase 1 NCT05781542 Apr 2023 → Oct 2024 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT05828095 Apr 2023 → Jan 2025 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT05470400 Aug 2022 → Jan 2024 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded
Phase 1 NCT04985760 Sep 2021 → Jan 2026 HIV infectious disease Madhu Chhanda Choudhary Completed No outcome recorded
Phase 1 NCT04177355 Jan 2020 → Nov 2024 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT03878121 Apr 2019 → Nov 2028 expected — National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1 NCT03783130 Mar 2019 → Jun 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Trimer 4571 “An intramuscular protein booster vaccination with the heterologous soluble trimeric protein VRC-HIVRGP096-00-VP (Trimer 4571) with alum will be administered to all vaccinees at month 6.” NCT03878121 ↗
6

NCT04177355 ↗

NCT05781542 ↗

NCT05828095 ↗

NCT05470400 ↗

NCT04985760 ↗

NCT06332339 ↗
Known as HIV-1 Trimer 4571 Vaccine “HIV-1 Trimer 4571 Vaccine” NCT04985760 ↗
Known as VRC-HIVRGP096-00-VP ClinicalTrials.gov intervention name — accepted as the source's own label NCT03878121 ↗
1

NCT03783130 ↗
Modality Vaccine “Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent” NCT04985760 ↗
Route Intramuscular “as a 1ml intramuscular injection at Day 0, Week 8 and Week 20” NCT04985760 ↗